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Introduction: Tobacco use is associated with poor outcomes in can-
cer patients, but there is little information from oncology providers 
on their practice patterns or perceptions regarding tobacco use and 
smoking cessation in these patients.
Methods: An online survey of practices, perceptions, and barriers to 
tobacco assessment and cessation in cancer patients was conducted 
in members of the International Association for the Study of Lung 
Cancer (IASLC). Responses of physician-level respondents were 
analyzed and reported.
Results: Responses from 1507 IASLC members who completed 
the survey are reported as representing 40.5% of IASLC members. 
More than 90% of physician respondents believe current smoking 
affects outcome and that cessation should be a standard part of clini-
cal care. At the initial patient visit, 90% ask patients about tobacco 
use, 79% ask patients whether they will quit, 81% advise patients 
to stop tobacco use, but only 40% discuss medication options, 39% 
actively provide cessation assistance, and fewer yet address tobacco 
at follow-up. Dominant barriers to physician cessation effort are pes-
simism regarding their ability to help patients stop using tobacco 
(58%) and concerns about patient resistance to treatment (67%). 
Only 33% report themselves to be adequately trained to provide ces-
sation interventions.
Conclusion: Physicians who care for lung cancer patients recognize 
the importance of tobacco cessation as a necessary part of clinical 
care, but many still do not provide assistance to their patients as a 
routine part of cancer care. Increasing tobacco cessation activities 
will require increased assessment and cessation at diagnosis and dur-
ing follow-up, increased clinician education, and improved tobacco 
cessation methods.
Key Words: Smoking, Tobacco, Survey, Thoracic, Oncologists, 
Cancer, Cessation.
(J Thorac Oncol. 2013;8: 543-548)
Incorporation of standardized tobacco use assessments into clinical practice has been advocated for several years but is 
not widely practiced. Many health care providers who treat 
cancer patients may assume that it is too late after diagnosis 
to intervene with cancer patients. However, continued smok-
ing has an adverse effect on cancer patients through increased 
complications from surgery, increased treatment-related tox-
icity, increased risk of recurrence, increased risk of second 
primary tumors, increased noncancer-related comorbidity and 
mortality, and decreased survival.1–7 Smoking after diagno-
sis also decreases quality of life for both cancer patients and 
caregivers of patients with lung or colorectal cancer.8 There 
are limited studies on the effects of smoking cessation in can-
cer patients, but data suggest that the effects of smoking are 
reversible.7,9–12 These data support the incorporation of smok-
ing cessation as standard clinical treatment for cancer patients.
The International Association for the Study of Lung 
Cancer (IASLC) is a global organization dedicated to 
the study and treatment of lung cancer. Founded in 1974, 
the association’s membership includes more than 3500 
multidisciplinary lung cancer specialists in 80 countries. 
IASLC members work to enhance the understanding of lung 
cancer among scientists, members of the medical community, 
and the public. Because tobacco smoking is such an important 
cause of lung cancer worldwide, IASLC continues to advocate 
policies that discourage the use of tobacco and works to 
educate its members about the importance of counseling 
patients to stop smoking. This article presents the results 
of an online survey of IASLC members conducted in 2012, 
to assess the tobacco assessment and cessation practices of 
members, and to identify perceptions about and potential 
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barriers to implementing tobacco cessation interventions for 
cancer patients.
MATERIALS AND METHODS
The study was approved by the Institutional Review 
Board at Roswell Park Cancer Institute (Buffalo, NY). A brief 
online questionnaire was developed to assess practice patterns 
and perceptions of IASLC members regarding tobacco use 
among cancer patients. The online survey included questions 
about respondent background characteristics (i.e., educa-
tional degree, area of clinical practice, primary work setting, 
percentage of time devoted to patient care, and years since 
completion of their most senior degree), and questions to 
assess the frequency of assessing tobacco use and providing 
tobacco cessation support at initial patient visit, frequency 
of assessing tobacco use at follow-up appointments, per-
ceived barriers to providing tobacco cessation interventions 
for cancer patients, and opinion or judgment statements on 
the relationship between tobacco and cancer. In addition, the 
survey asked about prior and current tobacco use of respon-
dents and the country where the respondent practiced. The 
full questionnaire is available in Supplementary Appendix 1 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A404).
The survey was distributed to the members of IASLC, 
using the online survey method. The survey was sent four 
times over a 6-week period as a means to increase partici-
pation. Respondents were given incentive for enrollment by 
drawing lots to win a free Ipad (Apple Inc.) sponsored by 
IASLC. The survey was conducted online through E-mail 
contact, and annotated answers were collated for analysis. Of 
the 3719 IASLC members invited to participate, 1507 (40.5%) 
completed the survey for this analysis.
Data Analysis
Analyses were restricted to respondents who had a 
medical degree (or equivalent) and who provided clinical 
care for cancer patients. Respondents who fit these criteria 
represented 87% of the total survey. Data were transferred to 
SAS 9.3 software (SAS Institute Inc., Cary, NC) for statisti-
cal analyses. The results presented were primarily based on 
descriptive analyses. Demographic variables were grouped 
for comparison between respondents and nonrespondents 
to assess whether respondents constituted a representative 
sample. Educational degrees were separated into medical, 
higher science, basic science, nursing, and pharmacy. Areas 
of specialty (i.e., primary area of clinical practice) was sep-
arated into surgery, medical oncology, radiation oncology, 
pulmonary medicine (including pulmonology, respirology, 
and pneumonology), and others. There were several coun-
tries of origin and they were grouped according to the of 
response. Countries representing less than 4% of responses 
(i.e., <60 respondents) were grouped according to continent. 
Australia, Canada, China, Japan, United Kingdom, and the 
United States were countries with at least 60 respondents.
Questions on the respondent’s smoking history were 
combined to form one variable that represented smoking sta-
tus. Respondents who answered the question, “Do you now 
smoke cigarettes every day, some days, or not at all?” with 
“Every day” or “Some days” were considered current smok-
ers. Respondents who answered “Not at all” to this question 
and stated that they had smoked at least 100 cigarettes in their 
life, were categorized as former smokers. Respondents who 
answered “Not at all” to the smoking status question, and 
“No” to at least 100 cigarettes smoked during their lifetime, 
were considered never smokers.
Comparison of respondent and nonrespondent charac-
teristics was used to gauge possible response bias. The signifi-
cance of difference was assessed by the χ2 test. Comparisons 
were based on academic degree, specialty, and country of 
practice because these variables were available for all the 
potential survey participants.
RESULTS
The characteristics of the respondents and nonrespon-
dents are shown in Table 1. Respondents differed from non-
respondents with regard to degree, specialty, and country. 
IASLC members, outside the United States, were more likely 
to respond to the survey than those from the United States. In 
addition, surgeons and medical oncologists were more likely 
to respond compared with respondents from other special-








1507 (40.5) 2212 (59.5)
Specialty Medical oncology 504 (33.4) 582 (26.3) <0.001
Pulmonary medicine 282 (18.7) 430 (19.4)
Radiation oncology 133 (8.8) 242 (10.9)
Surgery 366 (24.3) 445 (20.1)
Other 222 (14.7) 513 (23.2)
Degree Science 103 (6.8) 206 (9.3) <0.001
Medical doctrate 1306 (86.7) 1947 (88.0)
Nursing 37 (2.5) 20 (0.9)
Other 61 (4.0) 39 (1.8)
Country Australia 88 (5.8) 83 (3.8) <0.001
Canada 60 (4.0) 63 (2.8)
China 68 (4.5) 45 (2.0)
Japan 181 (12.0) 316 (14.3)
United Kingdom 68 (4.5) 87 (3.9)
United States 343 (22.8) 629 (28.4)
Africa 22 (1.5) 13 (0.6)
Asia (excluding  
Japan and China)
131 (8.7) 229 (10.4)
Europe 431 (28.6) 674 (30.5)
North America  
(excluding Canada  
and United States)
13 (0.9) 14 (0.6)
South America 90 (6.0) 59 (2.7)
Other countries 12 (0.8)
Significant differences between respondents and nonrespondents for each category 
was calculated using χ2 test with significance determined at p < 0.05.
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represented the primary respondent category (33%), most 
respondents (87%) had a medical degree, and 51% were from 
the United States or Europe.
Table 2 shows the practice characteristics and the his-
tory of tobacco use in the 1304 medical doctrate–level respon-
dents. Most respondents (70%) reported that they practiced 
medicine in a university or an academic setting, most (73%) 
had been in practice for more than 10 years, and most (77%) 
reported spending at least 50% of their time devoted to patient 
care. Although 70% of respondents reported a never-smoking 
history, there were 69 medical doctorate respondents (5%) 
who reported current tobacco use.
Tobacco use assessment is reported in Table 3. At the 
initial patient visit, an overwhelming majority of respondents 
reported that they ask patients whether they use tobacco (90% 
ask always or most of the time), whether they will quit (79% 
ask always or most of the time), and they also advise patients 
to stop tobacco use (81% advise always or most of the time). 
However, a lower percentage reported to discussing medication 
options (40% always or most of the time) and actively treating 
patients (39% always or most of the time). Questioning patients 
about tobacco use at follow-up was less frequently reported.
Respondent opinions on tobacco use in cancer patients 
are shown in Table 4. A large proportion of respondents 
reported that they believed current smoking by cancer 
patients affected outcomes (92% agree or strongly agree) and 
that tobacco cessation should be a standard part of clinical 
care (90% agree or strongly agree). In contrast, only 33% 
of respondents agreed or strongly agreed that they have had 
adequate training in cessation interventions, and 82% of the 
respondents agreed that clinicians needed more training in 
tobacco assessment and cessation.
Barriers to providing cessation interventions are 
reported in Table 5. Most respondents reported that inability 
to get patients to quit (58%) and patient resistance to treat-
ment (67%) were barriers to cessation interventions in cancer 
patients. Nonetheless, only 12% of the respondents believed 
that cessation was a waste of time. Lack of training or experi-
ence (48%), lack of available resources (48%), and lack of 
time (45%) were also cited as barriers to providing cessation.
DISCUSSION
These data suggest that, although physicians of thoracic 
oncology view tobacco use as affecting cancer outcomes and 
that tobacco cessation should be a standard part of clinical 
TABLE 2.  Practice and Tobacco Use Characteristics from 
Physician Respondents
Category Frequency (%) 







Years passed after completion of 
terminal degree





Tobacco use history Current smoker 69 (5.3)
Former smoker 314 (24.1)
Never smoker 915 (70.2)
Other 6 (0.5)








During an Initial Visit
Always (%) Most of the Time (%) Sometimes (%) Rarely (%) Never (%) N/A (%)
Ask patients whether they smoke or use  
tobacco products
927 (70.4) 260 (19.8) 36 (2.7) 9 (0.7) 4 (0.3) 80 (6.1)
Ask people who smoke or use tobacco whether  
they will quit tobacco use
656 (49.9) 382 (29.0) 143 (10.9) 41 (3.1) 17 (1.3) 77 (5.9)
Advise people who smoke or use tobacco  
products to stop smoking
659 (50.1) 402 (30.5) 136 (10.3) 30 (2.3) 11 (0.8) 78 (5.9)
Discuss medication options such as nicotine  
replacement, bupropion, varenicline, etc.
207 (15.7) 323 (24.5) 426 (32.4) 223 (16.9) 52 (4.0) 85 (6.5)
Actively treat or refer patients for smoking/tobacco  
use cessation intervention
229 (17.4) 282 (21.4) 386 (29.3) 243 (18.5) 80 (6.1) 96 (7.3)
During Follow-Up Appointments
Ask patients about current smoking or tobacco use 547 (41.6) 420 (31.9) 209 (15.9) 38 (2.9) 12 (0.9) 90 (6.8)
Ask patients whether they have quit smoking or  
stopped using tobacco
514 (39.1) 428 (32.5) 235 (17.9) 39 (3.0) 11 (0.8) 89 (6.8)
Ask patients whether they have relapsed back  
into tobacco use
422 (32.1) 403 (30.6) 283 (21.5) 101 (7.7) 19 (1.4) 88 (6.7)
Reinforce the importance of stopping tobacco use 496 (37.7) 435 (33.1) 228 (17.3) 56 (4.3) 14 (1.1) 87 (6.6)
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cancer treatment, they also are of the opinion that cancer 
patients are unable to stop tobacco use. According to these 
data, physicians frequently ask and advise, but infrequently 
assist with tobacco cessation. Data further suggest that 
physicians do not feel adequately prepared to deliver effective 
tobacco cessation support to their cancer patients. However, 
only 12% of the respondents among the IASLC physician 
members believe that smoking cessation is a waste of time.
Similar practice patterns for lung cancer patients have 
been noted in smaller studies. According to a survey of 71 
thoracic oncologists, 61% of providers did not provide ces-
sation assistance for metastatic lung cancer patients.13 In a 
survey of 74 oncology providers, 82.4% assessed tobacco 
at initial visit, but only 42.5% to 60.8% assessed tobacco 
at follow-up. Less than 30% of the oncology providers 
assisted with quitting (referral to cessation service, nicotine 
replacement, withdrawal assistance, or self-help materials), 
and 51.1% requested additional training in smoking cessa-
tion quite a bit or very much.14 Notably, 87.8% of respon-
dents reported ‘patient lack of motivation to quit’ and 84.7% 
reported ‘patients do not see quitting smoking as an immedi-
ate concern’ as barriers to implementing smoking cessation. 
Inadequate time (27% of respondents) and lack of reimburse-
ment (9.6% of respondents) were minor barriers to imple-
mentation.14 Our findings parallel these trends. Both studies 
demonstrated remarkably high levels of concern for tobacco 
use in cancer patients, but low levels of physician assistance 
for tobacco cessation. These data suggest that even among 
very motivated practitioners, there were significant deficits in 
providing cessation support to cancer patients.
The importance of the oncology physician in promot-
ing tobacco cessation has been emphasized in several reports. 
Among head and neck cancer patients, a doctor’s advice was 
shown to be an important patient-perceived reason for smoking 
cessation,15 and counseling at the time of diagnosis improved 
cessation rates.16 However, in the randomized trial of usual 
care versus a physician-led smoking cessation in 432 cancer 
patients from several cancer sites, a physician-led intervention 
did not improve the 7-day point prevalence defined cessation at 
12 months.17 Notably, patients with lung or head/neck cancer 
had a higher likelihood of quitting at 6 months as compared 
with other cancer patients, suggesting that physician-led ces-
sation support may be more effective in patients with tobacco-
related cancers. However, data from a separate study suggest 
that enhanced tobacco cessation through increased provider 
education resulted in improved tobacco assessment and cessa-
tion support, but unchanged quit rates.18
Effective tobacco cessation in cancer patients may 
involve several factors. Successful tobacco cessation is related 
to other comorbid conditions, such as degree of nicotine 
dependence, alcohol use, and psychiatric disease in cancer 
patients.19–23 Self-blame and facilitation by family members 
have also been associated with the effectiveness of tobacco 
cessation in cancer patients.24,25 A recent study demonstrated 
that cancer stage, treatment, comorbidity, insurance, edu-
cation, and emotional support were predictors for tobacco 
TABLE 4.  Physician Respondent Opinions on Tobacco Use and Cancer
Question Strongly Agree (%) Agree (%) No Opinion or Neutral (%) Disagree (%) Strongly Disagree (%)
Current smoking or tobacco use impacts  
treatment outcomes in cancer patients
561 (43.0) 636 (48.7) 75 (5.7) 27 (2.1) 7 (0.5)
Tobacco cessation should be a standard part  
of cancer treatment interventions
603 (46.2) 575 (44.0) 93 (7.1) 28 (2.1) 7 (0.5)
I have had adequate training in tobacco  
cessation interventions
81 (6.2) 346 (26.5) 367 (28.1) 430 (32.9) 82 (6.3)
Clinicians need more training in tobacco  
assessment and cessation interventions
290 (22.2) 785 (60.1) 162 (12.4) 61 (4.7) 8 (0.6)
I believe tobacco smoking is the primary  
cause of the current lung cancer burden
719 (55.1) 478 (36.6) 81 (6.2) 23 (1.8) 5 (0.4)
TABLE 5.  Physician Respondent Perceptions of Barriers to Providing Tobacco Cessation Interventions in Cancer Patients who 
Currently Smoke or Use Tobacco
Question Strongly Agree (%) Agree (%) No Opinion or Neutral (%) Disagree (%) Strongly Disagree (%)
Inability to get patients to quit tobacco use 154 (11.7) 615 (46.7) 266 (20.2) 212 (16.1) 69 (5.2)
Waste of time—cessation does not affect  
outcomes in cancer patients
18 (1.4) 138 (10.5) 150 (11.4) 491 (37.3) 519 (39.4)
Lack of time for counseling or to set up a referral 69 (5.2) 523 (39.7) 295 (22.4) 321 (24.4) 108 (8.2)
None or limited provider reimbursement 68 (5.2) 342 (26.0) 485 (36.9) 291 (22.1) 130 (9.9)
Patient resistance to cessation treatment 166 (12.6) 720 (54.7) 218 (16.6) 172 (13.1) 40 (3.0)
Lack of training or experience in tobacco  
cessation interventions
68 (5.2) 559 (42.5) 313 (23.8) 299 (22.7) 77 (5.9)
Lack of available resources or referrals for  
cessation interventions
99 (7.5) 526 (40.0) 260 (19.8) 339 (25.8) 92 (7.0)
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cessation in cancer patients.26 Successful tobacco cessation 
may require attention to demographic, comorbid, and cancer 
treatment related details; however, an increasingly active ces-
sation support should be the first step for oncologists to pro-
mote cessation for cancer patients.
Active cessation support by physicians could involve 
direct intervention by the physician or referral to a dedi-
cated tobacco cessation program. Our study demonstrates 
that only 33% of physicians agree or strongly agree that 
they have had adequate training in tobacco cessation inter-
ventions, and 82% agree or strongly agree that clinicians 
need more training in tobacco assessment and cessation 
interventions. However, less than 50% report lack of train-
ing or experience in tobacco cessation interventions as a 
barrier to providing cessation interventions. Collectively, 
these data suggest that increased clinician education may 
improve confidence in providing cessation support, but 
may not address physician-perceived barriers to cessation. 
As noted earlier, inability to get patients to quit and patient 
resistance to treatment were the dominant barriers per-
ceived to providing tobacco cessation. Overall, these data 
suggest that additional efforts to improve tobacco cessa-
tion should incorporate a combination of improved phy-
sician education and improved tobacco cessation methods 
for cancer patients. Enhancing tobacco cessation in cancer 
patients further involves clearly defining tobacco use with 
standardized assessments—assessing prior and current 
tobacco use, assessing tobacco use during and after cancer 
care, and providing structured tobacco cessation support 
to cancer patients who smoke.27 In our study, low rates of 
cessation support in motivated practitioners reinforces the 
need for system-level changes to include routine incorpo-
ration of tobacco assessment and cessation into standard 
cancer care. The need for these changes is supported by 
a recent survey demonstrating that approximately half of 
the cancer centers define tobacco use effectively but most 
cancer centers do not provide well-defined tobacco use 
treatment services to cancer patients.28 In cancer patients, 
increasing the efficacy of tobacco cessation should also 
consider degree of addiction, motivation to quit, comorbid 
psychological distress or comorbidity, social support, and 
the potential stigma of a new tobacco-related cancer diag-
nosis.29 Substantial research is required to develop better 
methods to enhance tobacco cessation support and efficacy 
in cancer patients.
In summary, these data show that thoracic oncology 
physicians recognize the importance of tobacco cessation as 
critical to cancer care, but many still do not provide a rou-
tine tobacco cessation assistance to cancer patients. Perceived 
inability to get patients to quit and lack of education for smok-
ing cessation seem to be dominant barriers in providing ces-
sation support. However, only 12% of respondents regard 
smoking cessation as a waste of time. Improving tobacco ces-
sation will require assessing tobacco use and providing ces-
sation support at diagnosis and during follow-up for cancer 
patients. Additional considerations to improve cessation sup-
port include increasing physician education, increasing the 
efficacy of tobacco cessation in cancer patients, and consider-
ing social support for cancer patients.
ACKNOWLEDGMENTS
The IASLC aided in the distribution and collection of sur-
vey data, and provided financial support for this research effort.
 This work was supported in part by funding from the 
American Cancer Society (MRSG-11-031-01-CCE), the 
National Cancer Institute (CA 016056, CA 016672, and CA 
097893), and the International Association for the Study of 
Lung Cancer (IASLC). 
The authors acknowledge the efforts of Kristin 
Richeimer and the staff of the IASLC central office for assis-
tance with administration and data management for the sur-
vey. The authors also recognize the membership of IASLC 
without which the survey could not have been completed.
REFERENCES
 1. Warren GW, Kasza KA, Reid ME, Cummings KM, Marshall JR. 
Smoking at diagnosis and survival in cancer patients. Int J Cancer 
2013;132:401–410.
 2. Park SM, Lim MK, Jung KW, et al. Prediagnosis smoking, obesity, 
insulin resistance, and second primary cancer risk in male cancer sur-
vivors: National Health Insurance Corporation Study. J Clin Oncol 
2007;25:4835–4843.
 3. Driver JA, Yung R, Gaziano JM, Kurth T. Chronic disease in men with 
newly diagnosed cancer: a nested case-control study. Am J Epidemiol 
2010;172:299–308.
 4. Jang S, Prizment A, Haddad T, Robien K, Lazovich D. Smoking and qual-
ity of life among female survivors of breast, colorectal and endometrial 
cancers in a prospective cohort study. J Cancer Surviv 2011;5:115–122.
 5. Wedlake LJ, Thomas K, Lalji A, et al. Predicting late effects of pelvic 
radiotherapy: is there a better approach? Int J Radiat Oncol Biol Phys 
2010;78:1163–1170.
 6. Gajdos C, Hawn MT, Campagna EJ, Henderson WG, Singh JA, Houston 
T. Adverse effects of smoking on postoperative outcomes in cancer 
patients. Ann Surg Oncol 2012;19:1430–1438.
 7. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation 
after diagnosis of early stage lung cancer on prognosis: systematic review 
of observational studies with meta-analysis. BMJ 2010;340:b5569.
 8. Weaver KE, Rowland JH, Augustson E, Atienza AA. Smoking concor-
dance in lung and colorectal cancer patient-caregiver dyads and quality of 
life. Cancer Epidemiol Biomarkers Prev 2011;20:239–248.
 9. Jerjes W, Upile T, Radhi H, et al. The effect of tobacco and alcohol and 
their reduction/cessation on mortality in oral cancer patients: short com-
munication. Head Neck Oncol 2012;4:6.
 10. Kuri M, Nakagawa M, Tanaka H, Hasuo S, Kishi Y. Determination of 
the duration of preoperative smoking cessation to improve wound healing 
after head and neck surgery. Anesthesiology 2005;102:892–896.
 11. Mayne ST, Cartmel B, Kirsh V, Goodwin WJ Jr. Alcohol and tobacco 
use prediagnosis and postdiagnosis, and survival in a cohort of patients 
with early stage cancers of the oral cavity, pharynx, and larynx. Cancer 
Epidemiol Biomarkers Prev 2009;18:3368–3374.
 12. Bjarnason GA, Mackenzie RG, Nabid A, et al.; National Cancer Institute 
of Canada Clinical Trials Group (HN3). Comparison of toxicity associ-
ated with early morning versus late afternoon radiotherapy in patients 
with head-and-neck cancer: a prospective randomized trial of the 
National Cancer Institute of Canada Clinical Trials Group (HN3). Int J 
Radiat Oncol Biol Phys 2009;73:166–172.
 13. Couraud S, Fournel P, Moro-Sibilot D, et al. Professional practice and 
accessibility to equipment in thoracic oncology. Results of a survey in 
Rhônes-Alpes region (France). Bull Cancer 2011;98:613–623.
 14. Weaver KE, Danhauer SC, Tooze JA, et al. Smoking cessation counsel-
ing beliefs and behaviors of outpatient oncology providers. Oncologist 
2012;17:455–462.
 15. Gritz ER, Carr CR, Rapkin DA, Chang C, Beumer J, Ward PH. A smok-
ing cessation intervention for head and neck cancer patients: trial design, 
patient accrual, and characteristics. Cancer Epidemiol Biomarkers Prev 
1991;1:67–73.
 16. Vander Ark W, DiNardo LJ, Oliver DS. Factors affecting smoking cessation 
in patients with head and neck cancer. Laryngoscope 1997;107:888–892.
548 Copyright © 2013 by the International Association for the Study of Lung Cancer
Warren et al. Journal of Thoracic Oncology  •  Volume 8, Number 5, May 2013
 17. Schnoll RA, James C, Malstrom M, et al. Longitudinal predictors of con-
tinued tobacco use among patients diagnosed with cancer. Ann Behav 
Med 2003;25:214–222.
 18. Gosselin MH, Mahoney MC, Cummings KM, et al. Evaluation of an 
intervention to enhance the delivery of smoking cessation services to 
patients with cancer. J Cancer Educ 2011;26:577–582.
 19. Gritz ER, Carr CR, Rapkin D, et al. Predictors of long-term smoking ces-
sation in head and neck cancer patients. Cancer Epidemiol Biomarkers 
Prev 1993;2:261–270.
 20. Chan Y, Irish JC, Wood SJ, et al. Smoking cessation in patients diagnosed 
with head and neck cancer. J Otolaryngol 2004;33:75–81.
 21. Cooley ME, Wang Q, Johnson BE, et al. Factors associated with smoking 
abstinence among smokers and recent-quitters with lung and head and 
neck cancer. Lung Cancer 2012;76:144–149.
 22. Duffy SA, Ronis DL, Valenstein M, et al. A tailored smoking, alcohol, 
and depression intervention for head and neck cancer patients. Cancer 
Epidemiol Biomarkers Prev 2006;15:2203–2208.
 23. Duffy SA, Scheumann AL, Fowler KE, Darling-Fisher C, Terrell JE. 
Perceived difficulty quitting predicts enrollment in a smoking-cessation 
program for patients with head and neck cancer. Oncol Nurs Forum 
2010;37:349–356.
 24. Christensen AJ, Moran PJ, Ehlers SL, Raichle K, Karnell L, Funk G. Smoking 
and drinking behavior in patients with head and neck cancer: effects of 
behavioral self-blame and perceived control. J Behav Med 1999;22:407–418.
 25. Cooley ME, Finn KT, Wang Q, et al. Health Behaviors, Readiness to 
Change, and Interest in Health Promotion Programs Among Smokers 
With Lung Cancer and Their Family Members: A Pilot Study. Cancer 
Nursing 2012 Jul 11. doi: 10.1097/NCC.0b013e31825e4359
 26. Park ER, Japuntich SJ, Rigotti NA, et al. A snapshot of smokers after lung 
and colorectal cancer diagnosis. Cancer 2012;118:3153–3164.
 27. Gritz ER, Dresler C, Sarna L. Smoking, the missing drug interaction in 
clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 
2005;14:2287–2293.
 28. Goldstein AO, Ripley-Moffitt CE, Pathman DE, Patsakham KM. Tobacco 
use treatment at the U.S. National Cancer Institute’s designated Cancer 
Centers. Nicotine Tob Res 2013;15:52–58.
 29. Cataldo JK, Dubey S, Prochaska JJ. Smoking cessation: an integral part 
of lung cancer treatment. Oncology 2010;78:289–301.
